Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPC | P11150 | 16/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 16/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19709505 | 0.86 | LIPC (0.56) | LIPCLIPGRAB9ANPC1CYP1A2 | |
| SCHEMBL20972710 | 0.85 | LIPG (0.44) | LIPCLIPG | |
| SCHEMBL20972694 | 0.83 | HPGD (0.44) | LIPCLIPGCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL19709504 | 0.80 | LIPG (0.75) | LIPCLIPG | |
| SCHEMBL16899495 | 0.79 | LIPG (0.51) | LIPCLIPG | |
| SCHEMBL19709507 | 0.78 | LIPC (0.74) | LIPCLIPG | |
| SCHEMBL16907859 | 0.75 | LIPG (0.55) | LIPCLIPG | |
| SCHEMBL18216850 | 0.71 | LIPG (0.54) | LIPCLIPG | |
| SCHEMBL15464609 | 0.70 | LIPC (0.51) | LIPCLIPGRAB9ANPC1CYP1A2 | |
| SCHEMBL489108 | 0.70 | RAB9A (0.52) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597370-B2 | 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190144403-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144403-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, LPL, CEL | LIPC 7/4885LIPG 1/4885RAB9A 4474/4885 |
| US-10597370-B2 | 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors | LIPG, LPL, CEL | LIPC 7/4885LIPG 1/4885RAB9A 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.